drugset / Trial / NCT00190983
A Trial for Patients With Advanced/Recurrent Cervical Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 700 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 900 mg/m2 | Intravenous |